Effect of recombinant human granulocyte colony stimulating factor on granulocytopenia induced by cytotoxic chemotherapy in patients with multiple myeloma.
{"title":"Effect of recombinant human granulocyte colony stimulating factor on granulocytopenia induced by cytotoxic chemotherapy in patients with multiple myeloma.","authors":"R Pogłód, M Kraj, S Maj","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>15 multiple myeloma patients with severe granulocytopenia after chemotherapy were treated with recombinant human granulocyte colony stimulating factor (Neupogen; Roche). Granulocyte colony stimulating factor (G-CSF) was given s.c. usually in a dose of 5 micrograms/kg for 5-14 (median:8) days. In all cases the increase in ANC was observed; one day after completing therapy the ANC ranged from 2.3 to 19.7 (mean: 10.3) x 10(9)/l. In 3 cases the ANC peak appeared during first (2-4) days of treatment, in one- on 14-th day after 10-day unsuccesful treatment. Generally, ANCs rapidly decreased after discontinuation of treatment to the values observed prior to the last chemotherapy. Both adverse events present in 9 patients and changes in monitored blood biochemistry components were moderate and reversible. In 3 cases symptoms of myeloma progression occurred. The study showed that G-CSF is an efficient and well tolerated drug, but also demonstrated its short-term action.</p>","PeriodicalId":76124,"journal":{"name":"Materia medica Polona. Polish journal of medicine and pharmacy","volume":"27 3","pages":"83-9"},"PeriodicalIF":0.0000,"publicationDate":"1995-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Materia medica Polona. Polish journal of medicine and pharmacy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
15 multiple myeloma patients with severe granulocytopenia after chemotherapy were treated with recombinant human granulocyte colony stimulating factor (Neupogen; Roche). Granulocyte colony stimulating factor (G-CSF) was given s.c. usually in a dose of 5 micrograms/kg for 5-14 (median:8) days. In all cases the increase in ANC was observed; one day after completing therapy the ANC ranged from 2.3 to 19.7 (mean: 10.3) x 10(9)/l. In 3 cases the ANC peak appeared during first (2-4) days of treatment, in one- on 14-th day after 10-day unsuccesful treatment. Generally, ANCs rapidly decreased after discontinuation of treatment to the values observed prior to the last chemotherapy. Both adverse events present in 9 patients and changes in monitored blood biochemistry components were moderate and reversible. In 3 cases symptoms of myeloma progression occurred. The study showed that G-CSF is an efficient and well tolerated drug, but also demonstrated its short-term action.